Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass) und in der intravasalen Phase („steady state) bei 3.OT

niversity of Bonn0 个研究点目标入组 50 人开始时间: 2007年8月15日最近更新: 2013年2月4日

试验速览

暂无简介。

•- male and female patients aged 18- 75 years
•- written, voluntary informed consent
•- patients are able to unterstand the meaning and consequences of the clinical trial
•- Indication MRT, MRA/DSA to represent the supraaortale vessels
•- GFR > or equal 60 ml/min (Cockroft Gault)
•- TSH normal range
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- MRT is not possible (e.g. cardiac pacemacer, cochlea implant etc.)
•- known or suspected pregnancy
•- breastfeeding women
•- Recent intracerebrale bleeding with suspected aneurysm or AV-malformation (has to be ruled out by CT, native)
•- Known anaphylactic or anaphylactoid reaction in history
•- life-threatening or haemodynamic instability
•- inadequate renal function
•- thyroid overactivity or hypothyreoidism
•- seizure disorder
•- untreated hypocaliaemia
•- Known history of HIV infection or chronic hepatitis B or C infection
•- participation in any other clinical trial within the last 3 months
•- alcohol and/or substance abuse
•- patients, who need an emergency therapy/current therapeutic intervention in the area that is to be tested within 24 hours following the initial diagnostics

发起方

niversity of Bonn